Acrivon Therapeutics is a Boston-area biotech founded in 2018, emerging with a mission to revolutionize cancer treatment through precision medicinestockanalysis.com. The company’s name “Acrivon” is derived from “accurate” or “precision,” reflecting its core approach: develop targeted oncology drugs hand-in-hand with diagnostics that pinpoint the patients who will respond. Acrivon’s proprietary platform, AP3, lies at the heart of this strategy. Using proteomics and AI tools, AP3 measures the activity of myriad proteins and signaling pathways inside tumor cells in their native state, rather than just analyzing DNA mutationsglobenewswire.comglobenewswire.com. This allows Acrivon to create drug-specific “OncoSignature” tests – essentially companion diagnostics that predict whether a patient’s tumor is susceptible to a given drugstockanalysis.comstockanalysis.com. It’s a novel twist on precision oncology: instead of the traditional focus on genetic markers, Acrivon’s proteomic signatures aim to capture real-time tumor biology to guide therapynasdaq.comglobenewswire.com.
